Dosage calculator
Menu ☰

Good questions. Plain English. Sources included.

← All peptide guides

Hormone signalling · Exact compound matters

CJC-1295

Fictional visual analogy: signal dispatcher
Fictional visual analogy: signal dispatcher

CJC-1295 is built around GHRH - the signal the brain uses to tell the pituitary to release growth hormone. So rather than injecting growth hormone itself, the idea is to ring headquarters and ask the body to send some of its own.

Educational guide · evidence level shown throughout

THE ONE-MINUTE PUB CHAT

THE GROWTH-HORMONE DISPATCHER

CJC-1295 is built around GHRH – the signal the brain uses to tell the pituitary to release growth hormone.

So rather than injecting growth hormone itself, the idea is to ring headquarters and ask the body to send some of its own.

The important bit is the label. True CJC-1295 with DAC has a drug-affinity complex that lets it hang around much longer. Products sold as 'CJC without DAC' are often referring to a shorter-acting GHRH analogue commonly called modified GRF(1-29).

In pub terms, one dispatcher has booked a room for the week; the other is popping in for twenty minutes and catching the last bus home.

Same general department. Very different timetable. Which is why 'CJC-1295' without checking the exact compound is about as useful as saying, 'I've bought a Ford.'

The joke is an analogy, not a clinical claim.

Overview illustrationQuick orientation

Evidence update: 6 October 2026

What is CJC-1295?

CJC-1295 is built around GHRH - the signal the brain uses to tell the pituitary to release growth hormone. So rather than injecting growth hormone itself, the idea is to ring headquarters and ask the body to send some of its own.

What it is / targetsGHRH-receptor agonism intended to stimulate pulsatile growth-hormone release; DAC and no-DAC products have materially different pharmacology.
What researchers studiedSmall physiological studies measured GH/IGF-1 responses, especially with long-acting CJC-1295 DAC.
Evidence snapshotExact compound matters

Why people are interested

The potential benefits, unpacked.

Here are the goals and claims that bring readers to this guide. The evidence note shows which part is demonstrated, early research or still a question.

The headline interest

Small physiological studies measured GH/IGF-1 responses, especially with long-acting CJC-1295 DAC.

What the mechanism suggests

GHRH-receptor agonism intended to stimulate pulsatile growth-hormone release; DAC and no-DAC products have materially different pharmacology.

What still needs proving

The key question is whether the claimed benefit has been demonstrated in controlled human studies using the same compound, route and population.

What is it actually doing?

GHRH-receptor agonism intended to stimulate pulsatile growth-hormone release; DAC and no-DAC products have materially different pharmacology.

The important distinction is between changing a biomarker or pathway and producing a meaningful outcome that people can feel, measure or sustain.

Mechanism is not outcome. A biologically interesting pathway does not by itself prove a useful effect in people.
Results illustrationResults at a glance

Human evidence

What did the studies actually find?

1 highlighted

Human study deep dive

The most informative human evidence we could identify is translated below, with the original source linked.

Study evidence illustrationStudy evidence

Study deep dives

The important studies, translated into normal English.

Each synopsis keeps the trial design, actual results and limitations together. Graphs below are redrawn from the cited numerical results so you can see the size of the effect without having to decode a journal figure.

Long-acting CJC-1295 in healthy adults — 2006

Two randomised placebo-controlled ascending-dose studies · 28–49 days

A single dose produced dose-dependent mean GH increases of roughly 2–10-fold for six days or more and IGF-1 increases of about 1.5–3-fold for 9–11 days. Estimated half-life was 5.8–8.1 days.

Peptalk takeaway

This is strong evidence that DAC CJC-1295 can alter the GH/IGF-1 axis; it is not evidence for bodybuilding, fat loss or anti-ageing outcomes.

Key result at a glanceRedrawn from the numerical results reported in the cited source.
GH increase (upper reported fold)
10
IGF-1 increase (upper reported fold)
3

What it doesn't prove: Healthy-volunteer hormone study, not a clinical-outcomes trial; does not apply automatically to “no-DAC” products.

Read the original study / source ↗
Dose comparison illustrationDosing reference

Research, licensed & reported protocols

What doses and schedules are actually documented?

Human research or licensed product information is separated from clinic and community practice. These are source-attributed reference protocols, not personalised dosing recommendations.

Human research / licensed or product dosing

Protocol / contextAmount & frequencyDurationTitrationEvidence
DAC CJC-1295 healthy-adultSingle ascending SC doses; repeatedSingle and 2–3Ascending cohortsHuman Phase 1
studyweekly/biweekly doses; 30 or 60 mcg/kg particularly well toleratedrepeated doses
PK findingHalf-life ~5.8–8.1 days in study——Human PK

Community / clinic / specialist protocols

PatternAmount & frequencyCycleProgressionStatus
DAC common~1–2 mg/week, often 1–2 administrations/week8–12 weeks commonly citedSome protocols Com 300→500→750 mcg→1 mg per administrationmunity
No-DAC / Mod GRF convention~100–300 mcg per dose, 1–3× daily8–12 weeksOften starts ~100 mcgCommunity; NOT the same schedule as DAC
Evidence reality check

The original human CJC-1295 data are for long-acting DAC CJC-1295. Do not use those PK data to validate no-DAC schedules.

Dosing sourcesHuman PK/dose study ↗Community DAC protocol example ↗

Evidence checked: 7 October 2026

Routes and formulations matter. A topical study does not validate injection; an IV research dose does not establish a fixed SC dose; and evidence for one molecular form must not be silently transferred to another.

Community reports illustrationCommunity reports

Community reports

What are people actually doing?

Anecdote, not evidence. These examples document community practice and experiences. They do not establish safety, efficacy or an appropriate dose.

Community experience exists, but is anecdotal

Forums discuss schedules, effects and side effects, but posts are uncontrolled self-reports and product identity may be uncertain. Use them to understand what people report—not to estimate efficacy or establish a dose.

View the discussion on Reddit ↗
Safety illustrationSafety and uncertainty

Safety, side effects & what we don't know

Exact compound identity matters; “CJC without DAC” is often used loosely for modified GRF(1-29).

Product identity, sterility and concentration are additional uncertainties for unlicensed research products. Evidence from an approved medicine or a clinical trial should not be transferred automatically to a differently sourced product.

Educational information only. Research compounds, trial protocols and community reports should not be treated as individual medical advice.
Questions illustrationQuestions

Questions worth asking

What is the strongest evidence here?

This is strong evidence that DAC CJC-1295 can alter the GH/IGF-1 axis; it is not evidence for bodybuilding, fat loss or anti-ageing outcomes.

Does a biological mechanism prove the claimed benefit?

No. Receptor activity, cell effects and animal results can justify research, but controlled human outcomes are a separate evidential step.

Is the research protocol a recommended dose?

No. The site reports study protocols to explain the evidence. It does not turn them into personalised self-use instructions.

Sources illustrationPrimary sources

Studies, sources & further reading

Long-acting CJC-1295 in healthy adults — 2006 ↗Search PubMed for CJC-1295 ↗Search ClinicalTrials.gov ↗

External links are provided for transparency and further reading. Linking to a study, discussion or organisation does not mean Peptides Peptalk endorses every conclusion on that page.